Project Grant R21AI199841
Award Date 5/21/26
Completion Date 4/30/28
Dollars Obligated $247K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,000 Project Grant to the University of Colorado-Denver under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 3, 2025, with a completion date of June 30, 2027. This research project delivers investigative services focused on understanding the pathogenic mechanisms of Type 1 Diabetes (T1D), specifically examining the role of pH levels in insulin-producing...
- Federal Grant Award Summary The University of Miami's Office of Research Administration received a $380,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, with a completion date of July 31, 2026. This award supports the development and evaluation of PS03, a bifunctional RNA therapeutic designed to modulate programmed death ligand 1 (PDL1) expression...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University $239,135 on August 11, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate a magnetics-based platform for high-speed mapping of tissue mechanical properties. The project, which will be conducted in New York and is scheduled for completion by July 31, 2027, addresses a critical technical limitation in understanding how...
- Federal Grant Award Summary Columbia University's Health Sciences Division received a $3.14 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 6, 2026, with completion targeted for January 31, 2030. The grant funds investigator-initiated biomedical research examining regulatory T cell (Treg) memory responses in human tissues. The research leverages an established...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Trustees of Columbia University in the City of New York $821,367 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a five-year project period commencing May 1, 2026 and concluding April 30, 2031. The award supports systematic functional variant mapping and phenotypic evaluation in genetic diseases of the immune system (GDIS), with emphasis on clarifying the...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Regents of the University of Colorado-Denver $634,984 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 10, 2025, for a project extending through June 30, 2030. This Project Grant funds investigator-initiated biomedical research aimed at uncovering the role of BND2 cells in Type 1 Diabetes (T1D) autoimmunity. The primary deliverables include scientific research...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Indiana University Indianapolis a $457,877 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 21, 2025, with an ultimate completion date of July 31, 2027. This award supports investigator-initiated research to identify and validate soluble lymphocyte activation gene-3 (sLAG-3) and insulin messenger RNA as potential biomarkers for early...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $429,000 to The Regents of the University of Colorado, doing business as University of Colorado-Denver, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, effective February 1, 2026, through January 31, 2028, funds research into the species-specific regulation of autoantigen processing in Type 1 Diabetes. The primary deliverable is the...
- Federal Project Grant Award Summary Antiger Therapeutics Inc. received a $606,548 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on August 11, 2025, with a completion date of January 31, 2027. This Small Business Innovation Research (SBIR) Phase I grant supports the development of peptide-human leukocyte antigen-DQ8 (PDQ8) biologics as targeted immunotherapies for Type 1...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $214,906 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research conducted from June 1, 2026, through May 30, 2028. This award supports the development of nanobodies—small, engineered antibody fragments derived from camelid heavy-chain-only antibodies—as...